Aratana Therapeutics (PETX) Misses Q4 EPS by 15c, Beats on Revenues; Offers FY18 Financial Guidance

Note: EPS may not be comparable

Aratana Therapeutics (NASDAQ: PETX) reported Q4 EPS of ($0.37), $0.15 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $10.46 million versus the consensus estimate of $6.82 million.

Financial Guidance

The Company expects approximately $35.0 million of cash to be used for on-going operations in 2018, as well as $17.3 million of cash to cover its existing debt principal obligations during the year. Aratana believes its current cash, cash equivalents, restricted cash and short-term investments of approximately $68.0 million as of December 31, 2017, together with the aggregate net proceeds of approximately $11.7 million from the sale of shares of the Company\'s common stock under its at-the-market sales agreement in January 2018, will be sufficient to fund its current operating plan and debt obligations through at least March 31, 2019.

For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance